Maxim Group analyst Jason McCarthy maintained a Buy rating on Brainstorm Cell Therapeutics (BCLI - Research Report) yesterday and set a price target of $8.00. The company's shares opened today at $4.33.According to TipRanks, McCarthy is an analyst with an average return of -37.8% and a 15.23% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as Adial Pharmaceuticals, Mesoblast, and Atossa Therapeutics.The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Brainstorm Cell Therapeutics with a $8.00 average price target.See the top stocks recommended by analysts >>The company has a one-year high of $4.70 and a one-year low of $2.52.
https://www.tipranks.com/news/blurbs/maxim-group-remains-a-buy-on-brainstorm-cell-therapeutics-bcli?utm_source=advfn.com&utm_medium=referral
Brainstorm Cell Therapeu... (NASDAQ:BCLI)
Historical Stock Chart
From Nov 2022 to Dec 2022 Click Here for more Brainstorm Cell Therapeu... Charts.
Brainstorm Cell Therapeu... (NASDAQ:BCLI)
Historical Stock Chart
From Dec 2021 to Dec 2022 Click Here for more Brainstorm Cell Therapeu... Charts.